$TCRX News

TScan Therapeutics Partners With Cellares To Evaluate Automated Clinical Manufacturing Of TSC-101, The Company's Lead TCR-T Therapy Candidate For Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes

TScan Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $982.000K Miss $2.500M Estimate

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space

Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Earnings Breakdown: TScan Therapeutics Q4

TScan Therapeutics' Cash And Cash Equivalents Of $152.4M To Provide Cash Runway Into 2H Of 2027

TScan Therapeutics' Cash And Cash Equivalents Of $152.4M To Provide Cash Runway Into 2H Of 2027

TScan Therapeutics Q4 2025 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate

TScan Therapeutics Q4 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

TScan Therapeutics Completes Enrollment Into Cohort C Of ALLOHA Study

TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

TScan Therapeutics Announced Saturday, Updated Data from the ALLOHA Phase 1 Heme Trial; 3/3 Of TSC-101-treated Patients Who Reached Two-year Follow-up Remained Relapse-free Vs. 1/4 In Control Arm

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $7

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates